Alios BioPharma

Virology-focused Enanta Pharmaceuticals, Inc. took a positive step in its two-mechanism approach to providing a treatment for respiratory syncytial virus (RSV) on 26 September as its RSV L-protein i

Shionogi & Co. Ltd. 's novel influenza drug Xofluza (baloxavir marboxil) has met its primary endpoint in a Phase III trial which looked at its ability to halt symptoms in people already exposed to t

After Roche acquired Genentech Inc. and focused its attention largely on oncology drugs, Jim Wu, a US-trained biochemist who returned to China to work for Roche, saw opportunities in the Swiss dru

Johnson & Johnson has taken a further $700m impairment charge after the failure of its respiratory syncytial virus (RSV) asset AL-8176 (lumicitabine) which it obtained via its 2014 acquisition of Al